MX2010001141A - Analogos fosforiladosde pirona y metodos. - Google Patents

Analogos fosforiladosde pirona y metodos.

Info

Publication number
MX2010001141A
MX2010001141A MX2010001141A MX2010001141A MX2010001141A MX 2010001141 A MX2010001141 A MX 2010001141A MX 2010001141 A MX2010001141 A MX 2010001141A MX 2010001141 A MX2010001141 A MX 2010001141A MX 2010001141 A MX2010001141 A MX 2010001141A
Authority
MX
Mexico
Prior art keywords
phosphorylated
methods
pyrone analogs
compositions
phosphorylated pyrone
Prior art date
Application number
MX2010001141A
Other languages
English (en)
Inventor
Wendye Robbins
Ving Lee
Original Assignee
Limerick Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Limerick Biopharma Inc filed Critical Limerick Biopharma Inc
Publication of MX2010001141A publication Critical patent/MX2010001141A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a polifenoles fosforilados, flavonoides fosforilados y análogos de pirona fosforilados. Se describen métodos y composiciones para la modulación de los efectos secundarios de sustancias utilizando tales compuestos tosforilados. Se describen métodos y composiciones para la modulación de la actividad transportadora de barrera hematohística (BTB) para incrementar el flujo de fármacos y otros compuestos fuera de un compartimento fisiológico y hacia un ambienteexterno. En particular, los métodos y composiciones descritos en la presente proporcionan efectos secundarios disminuidos cuando se co-administran análogos de pirona fosforilados con los agentes terapéuticos.
MX2010001141A 2007-07-31 2008-07-30 Analogos fosforiladosde pirona y metodos. MX2010001141A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95318807P 2007-07-31 2007-07-31
US7660808P 2008-06-27 2008-06-27
PCT/US2008/071588 WO2009018338A2 (en) 2007-07-31 2008-07-30 Phosphorylated pyrone analogs and methods

Publications (1)

Publication Number Publication Date
MX2010001141A true MX2010001141A (es) 2010-03-01

Family

ID=40305253

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001141A MX2010001141A (es) 2007-07-31 2008-07-30 Analogos fosforiladosde pirona y metodos.

Country Status (13)

Country Link
US (3) US7947733B2 (es)
EP (1) EP2182957A4 (es)
JP (1) JP2011500512A (es)
KR (1) KR20100051829A (es)
CN (1) CN101969959A (es)
AU (1) AU2008282261A1 (es)
BR (1) BRPI0814876A2 (es)
CA (1) CA2693338A1 (es)
GB (1) GB2464645B (es)
MX (1) MX2010001141A (es)
TW (1) TW200924785A (es)
WO (1) WO2009018338A2 (es)
ZA (1) ZA201001390B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0814876A2 (pt) 2007-07-31 2014-09-30 Limerick Biopharma Inc Análogos de pirona fosforilados e métodos
WO2009018320A1 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Pyrone analog compositions and methods
US20100189653A1 (en) * 2008-10-10 2010-07-29 Wendye Robbins Pyrone analogs for therapeutic treatment
WO2010129138A2 (en) * 2009-04-27 2010-11-11 Limerick Biopharma Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
AU2011242689B2 (en) 2010-04-23 2015-09-17 Kineta, Inc. Anti-viral compounds
WO2012068539A1 (en) * 2010-11-19 2012-05-24 Limerick Biopharma, Inc. Use and composition of quercetin-3'-o-sulfate for therapeutic treatment
EP2918273B1 (en) 2011-02-25 2016-12-21 Kineta, Inc. Methods and cells for identifying rig-i pathway regulators
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN104530127B (zh) * 2014-12-12 2016-09-14 广东东阳光药业有限公司 一种淫羊藿苷衍生物及其使用方法和用途
CN106632479B (zh) * 2016-12-22 2018-10-23 贵州大学 O,o’-二烷基-o”-(取代黄酮-3-基)磷酸酯类衍生物、制备方法及应用
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US10881634B2 (en) * 2017-12-07 2021-01-05 Hughes Biotechnology Co., Ltd Method for treatment or prevention of a disease associated with a decrease in bone mass and method of improving bone architecture and bio mechanical strength of bone
EP3955936A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Treatment of depression and other various disorders with psilocybin

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR837588A (fr) 1938-03-25 1939-02-14 Perfectionnements aux chaînes ou garnitures anti-patinantes et anti-dérapantes pour roues de véhicules
US2764596A (en) * 1952-07-01 1956-09-25 Nat Drug Co Inorganic acid esters of polyhydroxylated flavones and flavanones
US4530844A (en) * 1984-07-26 1985-07-23 Warner-Lambert Company Synergistic non-steroidal anti-inflammatory compounds and compositions thereof
JPH01153695A (ja) 1987-12-11 1989-06-15 Showa Denko Kk ルチンまたはケルセチンリン酸エステルの製造法
JPH01308476A (ja) 1988-06-06 1989-12-13 Showa Denko Kk 紫外線吸収剤
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US5643901A (en) * 1990-06-11 1997-07-01 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating idiopathic thrombocytopenic purpura
US5348966A (en) * 1990-10-24 1994-09-20 Fujisawa Pharmaceutical Co., Ltd. Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds
US5817333A (en) * 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
JPH07509442A (ja) 1991-11-18 1995-10-19 メレルダウファーマスーティカルズ　インコーポレイテッド ウィルス病処置でのホスホリル化フラボノイド類
JPH072826A (ja) 1992-03-12 1995-01-06 Sanwa Kagaku Kenkyusho Co Ltd フラボン誘導体
US5972598A (en) * 1992-09-17 1999-10-26 Board Of Trustess Of The University Of Illinois Methods for preventing multidrug resistance in cancer cells
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
US6362160B1 (en) * 1993-06-30 2002-03-26 The Johns Hopkins University School Of Medicine Immunophilin-binding agents prevent glutamate neurotoxicity associated with vascular stroke and neurodegenerative diseases
US6022852A (en) * 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
AU4515996A (en) 1995-01-09 1996-07-31 Alpha-Therapeutics, Inc. Methods for increasing the bioavailability of biological active agents
DK0914102T3 (da) * 1996-05-24 2006-01-09 Angiotech Pharm Inc Præparater og fremgangsmåder til behandling eller forebyggelse af syddomme i legemskanaler
GB9613455D0 (en) * 1996-06-27 1996-08-28 Aston Molecules Ltd Analogues or derivatives of quercetin
US6201165B1 (en) * 1997-10-16 2001-03-13 Board Of Regents, University Of Texas System Transgenic animal models for cardiac hypertrophy and methods of use thereof
US6013621A (en) * 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
PL340736A1 (en) 1997-12-03 2001-02-26 Fujisawa Pharmaceutical Co Drug in the form of soft granules and method of obtaining same
WO1999042104A1 (en) * 1998-02-23 1999-08-26 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for treating glaucoma
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
US6458777B1 (en) * 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
RU2214244C9 (ru) * 1998-03-26 2020-07-29 Астеллас Фарма Инк. Препараты с замедленным высвобождением
EP1067926A2 (en) * 1998-04-06 2001-01-17 Fujisawa Pharmaceutical Co., Ltd. Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins
GB9814640D0 (en) 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
AUPP584198A0 (en) * 1998-09-14 1998-10-08 Fujisawa Pharmaceutical Co., Ltd. New use
WO2000023102A1 (en) 1998-10-19 2000-04-27 New York University Method for regulating the permeability of the blood brain barrier
US6864232B1 (en) * 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
JP2002535410A (ja) 1999-01-27 2002-10-22 ザィエリンスキ，ラブラトリー 高められたバイオアベイラビリティーを有するヘスペレチンプロフォーム
TR200102778T2 (tr) * 1999-03-11 2002-05-21 Fujisawa Pharmaceutical Co. Ltd. Lipozom preparatları
IL146285A0 (en) * 1999-05-25 2002-07-25 Fujisawa Pharmaceutical Co Method for separating analogous organic compounds
AUPQ078799A0 (en) * 1999-06-04 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. New use
FI20000004A0 (fi) * 2000-01-03 2000-01-03 Slk Foundation Flavonoidilääke...
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
JP2004510694A (ja) * 2000-05-08 2004-04-08 ヘインズ　デイビッド 免疫抑制性組成物
FR2815033B1 (fr) * 2000-10-06 2003-09-05 Negma Lab Derives de 7-carboxy-flavones, porcede pour leur preparation et leur application en therapeutique
DE10056400A1 (de) * 2000-11-14 2002-05-23 Merck Patent Gmbh Galenische Formulierung
US20040091477A1 (en) * 2001-05-08 2004-05-13 David Haines Immunosuppresive compositions
CN1668287B (zh) * 2001-09-06 2012-03-28 赛诺克思公司 3-脱氧类黄酮在制备抑制t淋巴细胞活性的药物中的用途
US20040102386A1 (en) * 2001-09-06 2004-05-27 Thomas Lahey Inhibition by 3-deoxyflavonoids of T-lymphocyte activation and therapies related thereto
GB0125532D0 (en) 2001-10-24 2001-12-12 Burton Michael Enzyme activity indicators
TW200306826A (en) * 2002-01-10 2003-12-01 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
GB2391473B (en) * 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
US20060100179A1 (en) * 2002-08-14 2006-05-11 Pero Ronald W Compositions and methods for use in targeting vascular destruction
US20050080021A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
DE10240923A1 (de) 2002-09-02 2004-03-04 Merck Patent Gmbh Flavonoid-Derivate zur Ekzem-Behandlung
US20040209850A1 (en) * 2003-04-15 2004-10-21 Theraquest Biosciences, Llc Methods of treating pain and compositions for use therefor
US20050008640A1 (en) * 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
MXPA05013324A (es) * 2003-06-10 2006-03-09 Astellas Pharma Inc Preparacion de aerosol comprendiendo un anexo que incluye una composicion de aerosol conteniendo compuesto macrolido.
US20070099826A1 (en) * 2003-10-10 2007-05-03 Norman Wong Treatment of diseases associated with the egr-1 enhancer element
DE102004002787A1 (de) 2004-01-19 2005-08-11 Merck Patent Gmbh Flavonoid-Komplexe
WO2005075449A1 (en) * 2004-02-03 2005-08-18 Yale University Compounds and methods to increase anti-p-glycoprotein activity of baicalein by alkylation on the a ring
CN1297552C (zh) 2004-03-11 2007-01-31 南京莱尔生物化工有限公司 木犀草素的合成方法
JP2008506656A (ja) 2004-07-16 2008-03-06 ノバルティス アクチエンゲゼルシャフト 皮膚透過性の亢進のためのステロイドの使用
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
MX2007003126A (es) * 2004-09-14 2007-08-02 Ajinomoto Omnichem S A Composiciones topicas que contienen polifenoles fosforilados.
US20060069042A1 (en) * 2004-09-24 2006-03-30 Hu Oliver Y Cytochrome P450 2C9 inhibitors
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
EP1817023A4 (en) * 2004-11-16 2010-08-18 Limerick Biopharma Inc METHOD AND COMPOSITIONS FOR PAIN TREATMENT
US20070087977A1 (en) 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
DK1856085T3 (en) * 2005-03-11 2015-10-05 Howard Florey Inst Pty Ltd FLAVONOID COMPOUNDS AND APPLICATIONS THEREOF
US20080242599A1 (en) 2005-05-03 2008-10-02 Majd Zayzafoon Compositions and Methods for Increasing Osteoblast Cell Differentiation and Bone Generation
EP1909788A2 (en) * 2005-07-29 2008-04-16 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2007084857A2 (en) 2006-01-13 2007-07-26 President And Fellows Of Harvard College Methods and compositions for treating cell proliferative disorders
EP2591775A1 (en) 2006-04-05 2013-05-15 Novartis AG Combinations comprising mtor inhibitors for treating cancer
GB0618168D0 (en) 2006-09-15 2006-10-25 Babraham Inst Compounds
US20080153819A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
CN101573109A (zh) * 2006-12-28 2009-11-04 利默里克生物制药公司 用于治疗的方法和组合物
BRPI0814876A2 (pt) 2007-07-31 2014-09-30 Limerick Biopharma Inc Análogos de pirona fosforilados e métodos
US20090082400A1 (en) * 2007-07-31 2009-03-26 Ving Lee Soluble pyrone analogs methods and compositions
WO2009018320A1 (en) 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Pyrone analog compositions and methods
WO2009158031A2 (en) * 2008-06-27 2009-12-30 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
WO2009158007A2 (en) * 2008-06-27 2009-12-30 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
US20100297020A1 (en) * 2008-10-10 2010-11-25 Limerick Biopharma, Inc. Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
US20100189653A1 (en) * 2008-10-10 2010-07-29 Wendye Robbins Pyrone analogs for therapeutic treatment
WO2010129138A2 (en) 2009-04-27 2010-11-11 Limerick Biopharma Phosphorylated and phosphonated pyrone analogs for therapeutic treatment

Also Published As

Publication number Publication date
ZA201001390B (en) 2011-05-25
CN101969959A (zh) 2011-02-09
GB201002044D0 (en) 2010-03-24
TW200924785A (en) 2009-06-16
WO2009018338A2 (en) 2009-02-05
JP2011500512A (ja) 2011-01-06
AU2008282261A1 (en) 2009-02-05
GB2464645A (en) 2010-04-28
US7947733B2 (en) 2011-05-24
EP2182957A2 (en) 2010-05-12
US20090069273A1 (en) 2009-03-12
GB2464645B (en) 2010-11-24
KR20100051829A (ko) 2010-05-18
CA2693338A1 (en) 2009-02-05
EP2182957A4 (en) 2012-07-18
BRPI0814876A2 (pt) 2014-09-30
WO2009018338A3 (en) 2010-11-11
US20100204089A1 (en) 2010-08-12
US20100144612A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
GB2464645A (en) Phosphorylated pyrone analogs and methods
WO2009018326A3 (en) Soluble pyrone analogs methods and compositions
MX2013000567A (es) Composiciones farmaceuticas de moduladores de c-met.
BR112013016204A2 (pt) composições de ingredientes ativos solúveis em gordura que contêm complexos de proteína vegetal-polissacarídeo de soja.
WO2012009723A8 (en) C-met modulator pharmaceutical compositions
HK1164059A1 (en) Compositions for drug administration
EP2045251A4 (en) COMPOUNDS WHICH CAN INCLUDE THE UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
IL205360A0 (en) Methods, kits, and compositions for administering pharmaceutical compounds
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
NZ608673A (en) Therapeutic use of a tlr agonist and combination therapy
BRPI1006825A2 (pt) compostos pró-neurogênicos
EP2522653A4 (en) BIGUANIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE SUBSTANCE
MX2010003470A (es) Metodos y formulaciones para convertir farmacos intravenosos e inyectables en formas de dosificacion orales.
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
TN2012000392A1 (en) Oral formulations and lipophilic salts of methylnaltrexone
MX367640B (es) Tratamiento combinado del cáncer.
PL2083809T3 (pl) Kompozycja dietetyczna lub farmaceutyczna zawierająca tricykliczne diterpeny do leczenia depresji
JO2721B1 (en) Derivatives of artemisia plant and its preparations and therapeutic applications
IL217500A0 (en) Tetrazole derivatives, their preparartion and pharmaceutical compositions containing them
BRPI0917502A2 (pt) composição farmacêtica, e, métodos para usar um ácido orgânico ou um antioxidante, para evitar a descoloração causada quando ácido tranemaxâmico e ácido ascórbico são incorporados em uma mesma composição, e para produzir uma preparação farmacêutica sólida para administração oral
EP2241569A4 (en) THIENOPYRIDAZINE COMPOUNDS, PREPARATIONS THEREOF, PHARMACEUTICAL COMPOSITIONS AND USES
EP2478909A4 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING BISPHOSPHONATE DERIVATIVES AND HIGH-DOSE CHOLECALCIFEROL
WO2009158007A3 (en) Methods and compositions for therapeutic treatment
ZA200807486B (en) Medicament formulations comprising fluoroquinolones

Legal Events

Date Code Title Description
FA Abandonment or withdrawal